Market open
Athira Pharma/$ATHA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Athira Pharma
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Ticker
$ATHA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
66
Website
Athira Pharma Metrics
BasicAdvanced
$16M
-
-$2.85
2.83
-
Price and volume
Market cap
$16M
Beta
2.83
52-week high
$4.21
52-week low
$0.41
Average daily volume
197K
Financial strength
Current ratio
2.955
Quick ratio
2.54
Long term debt to equity
1.584
Total debt to equity
2.282
Management effectiveness
Return on assets (TTM)
-51.60%
Return on equity (TTM)
-102.87%
Valuation
Price to book
0.28
Price to tangible book (TTM)
0.28
Price to free cash flow (TTM)
-0.166
Growth
Earnings per share change (TTM)
-10.26%
3-year earnings per share growth (CAGR)
29.97%
What the Analysts think about Athira Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Athira Pharma stock.
Athira Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Athira Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Athira Pharma News
AllArticlesVideos
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
GeekWire·2 months ago
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Athira Pharma stock?
Athira Pharma (ATHA) has a market cap of $16M as of February 25, 2025.
What is the P/E ratio for Athira Pharma stock?
The price to earnings (P/E) ratio for Athira Pharma (ATHA) stock is 0 as of February 25, 2025.
Does Athira Pharma stock pay dividends?
No, Athira Pharma (ATHA) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Athira Pharma dividend payment date?
Athira Pharma (ATHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Athira Pharma?
Athira Pharma (ATHA) has a beta rating of 2.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.